MARKET

IPHA

IPHA

INNATE PHARMA SA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.980
+0.031
+0.78%
Closed 16:00 09/21 EDT
OPEN
3.900
PREV CLOSE
3.949
HIGH
4.050
LOW
3.900
VOLUME
12.52K
TURNOVER
--
52 WEEK HIGH
8.24
52 WEEK LOW
3.300
MARKET CAP
313.94M
P/E (TTM)
-5.4580
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cassava Sciences, Evogene leads the healthcare gainers' pack, Ayala Pharmaceuticals, Clovis Oncology amond major losers
Gainers: Cassava Sciences (SAVA) +41%, Evogene (EVGN) +26%, AlloVir (ALVR) +15%, Abeona Therapeutics (ABEO) +15%, Sonoma Pharmaceuticals (SNOA) +14%.Losers: Ayala Pharmaceuticals (AYLA) -12%, Clovis Oncology (CLVS) -10%, Checkpoint Therapeutics (CKPT) -9%, Seres Therapeutics (MCRB) -8%, Innate Pharma (IPHA) -5%.
Seekingalpha · 3d ago
Intra-Cellular Therapies, Trillium Therapeutics leads gainers, Co-Diagnostics, Applied Genetic Technologies among losers
Gainers: Intra-Cellular Therapies (ITCI) +65%, Trillium Therapeutics (TRIL) +36%, Amryt Pharma (AMYT) +25%, BeyondSpring (BYSI) +18%, XTL Biopharmaceuticals (XTLB) +17%.Losers: Co-Diagnostics (CODX) -17%, Applied Genetic Technologies (AGTC) -16%, SCWorx (WORX) -10%, Innate Pharma (IPHA) -7%, PolarityTE (PTE) -5%.
Seekingalpha · 09/09 15:07
Albireo Pharma, SCWorx leads gainers' pack, Corbus Pharmaceuticals, Innate Pharma among losers
Gainers: Albireo Pharma (ALBO) +40%, SCWorx (WORX) +35%, Co-Diagnostics (CODX) +27%, Nano-X Imaging (NNOX) +13%, Spero Therapeutics (SPRO) +11%,.Losers: Corbus Pharmaceuticals Holdings (CRBP) -76%, Innate Pharma (IPHA) -27%, Strongbridge Biopharma (SBBP) -22%, Biocept (BIOC) -17%, Community Health Systems (CYH) -10%.
Seekingalpha · 09/08 15:09
Innate Pharma reports first half 2020 financial results and business update
* Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoides * Monalizumab Phase 3 study expected to initiate in the second half of 2020, triggering $50 million milestone payment * Innate to explore avdoralimab in inflammation beyond
GlobeNewswire · 09/08 05:00
Upcoming Investor Conferences
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announces that it plans to participate in the following upcoming virtual investor conferences in September 2020: * Citi’s 15th Annual BioPharma Virtual Conference – September 08-11, 2020 * Goldman
GlobeNewswire · 09/04 06:00
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 08/11 12:20
Innate Pharma Announces Publication of EXPLORE COVID-19 Translational Study Findings in Nature
New research suggests targeting C5a-C5aR1 axis could limit severe inflammatory responseMARSEILLE, France, July 29, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced th
GlobeNewswire · 07/29 09:30
Innate Pharma Announces the Appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer
MARSEILLE, France, July 16, 2020 -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the appointment of Dr..
GlobeNewswire · 07/16 05:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IPHA stock price target is 10.84 with a high estimate of 17.44 and a low estimate of 5.98.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 3.04M
% Owned: 3.85%
Shares Outstanding: 78.88M
TypeInstitutionsShares
Increased
2
26.57K
New
3
-4.33M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman - Supervisory/Director
Herve Brailly
Chairman - Management/Chief Executive Officer
Mondher Mahjoubi
Vice Chairman - Supervisory/Independent Director
Irina Staatz-Granzer
Chief Financial Officer/Executive Vice President/Executive Board/IR Contact Officer
Laure-Hélène Mercier
Chief Financial Officer/Executive Vice President/Executive Board/IR Contact Officer
Laure-Helene Mercier
Executive Vice President/Vice President - Business Development/Executive Board
Yannis Morel
Executive Vice President/General Manager/Executive Board
Jennifer Butler
Executive Vice President/Executive Board
Joyson Karakunnel
Senior Vice President/Chief Scientific Officer/Executive Board
Eric Vivier
Vice President/Director of Human Resources/Executive Board
Odile Laurent
Vice President/Executive Board
Odile Belzunce
Vice President/Executive Board
Frederique Brune
Vice President/Executive Board
Tracy Rossin
Independent Director/Supervisory Board
Gilles Brisson
Independent Director/Supervisory Board
Veronique Chabernaud
Independent Director/Supervisory Board
Patrick Langlois
Supervisory Board
Jean-Yves Blay
Supervisory Board
Mailys Ferrere
Supervisory Board
Marcus Schindler
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average IPHA stock price target is 10.84 with a high estimate of 17.44 and a low estimate of 5.98.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IPHA
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Innate Pharma SA (ADR) stock information, including NASDAQ:IPHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IPHA stock methods without spending real money on the virtual paper trading platform.